ArticleCirculation reports2019

12-Week Effectiveness and Safety of Low-Density Lipoprotein Cholesterol-Lowering Therapy by Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition in Patients With Familial Hypercholesterolemia and Hypercholesterolemia　- Data From a Real-World Observational Study of Evolocumab in Japan.

Koutaro Yokote et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.